@Snow123This is a not a revenue ann but it is still a positive ann for its core bread n butter biz... the kind that brings in the regular millions on the side once it gets underway across multiple locations + regular supply orders..
HIV biz is the long game..AT1 was building its HIV production capacity for last 12mths (without which those extra millions won't generate at all) + it needed to pass the stringent audit stds to get factory fully functional + its continuing to build its brand and test awareness across multiple channels where folks will use/need/depend on HIV tests...
Incl the existing partnerships, AT1 (despite being a minnow) is driving towards HIV test presence is almost all the countries where HIV testing is needed...160+ countries + being part of the global health body procurement process. Once its test is approved, established and well known in countries/markets, it can release updated tests, new device versions, value add e-reader & telehealth capabilities....the process becomes much easier & rev margin exponentially higher.
AT1 would need to get a global WHO/gov tender for a substantial number of HIV tests to breach the current material rev cap (FY20 annual figure)...that's always possible & a WHO purchase tender is one of the current goals. That would be the rev ann (in the HIV space) to potentially shift SP north just based on news (by how much no one knows)...
For the long game, AT1 has shown steady progress on everything it has aimed for to date...
